Lung cancer • 7: Management of lung cancer in elderly patients

Thorax

Volumn 58, Issue 8, 2003, Pages 711-720

  Booton, R ^a   Jones, M ^b   Thatcher, N ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIPROFLOXACIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM; ROXITHROMYCIN; TOPOTECAN; VINCRISTINE;

ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ELDERLY CARE; FEBRILE NEUTROPENIA; FIBEROPTIC BRONCHOSCOPY; HUMAN; LUNG BIOPSY; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THORACOTOMY; AGED; LUNG TUMOR; SMALL CELL CARCINOMA; SURVIVAL;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 0041732426     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.58.8.711     Document Type: Review

References (159)

1. Brown JS, Eraut D, Trask C, et al. Age and the treatment of lung cancer. Thorax 1996;51:564-8.
2. Stephens RJ, Johnson DH. Treatment and outcomes for elderly patients with small cell lung cancer. Drugs Aging 2000;17:229-47.
3. Deppermann K. Influence of age and comorbidities on the chemotherapeutic management of lung cancer. Lung Cancer 2001;33(Suppl 1):S115-20.
4. Stone P, Hardy J, Broadley K, et al. Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br J Cancer 1999;79:1479-86.
5. O'Driscoll M, Corner J, Bailey C. The experience of breathlessness in lung cancer. Eur J Cancer Care 1999;8:37-43.
6. Coebergh JW, Janssen-Heijnen ML, Post PN, et al. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. J Clin Epidemiol 1999;52:1131-6.
7. Janssen-Heijnen ML, Schipper RM, Razenberg PP, et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998;21:105-13.
8. Kurishima K, Satoh H, Ishikawa H, et al. Lung cancer in middle-aged patients. Oncol Rep 2001;8:851-3.
9. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000;117:1239-46.
10. Kurishima K, Satoh H, Ishikawa H, et al. Lung cancer patients with chronic obstructive pulmonary disease. Oncol Rep 2001;8:63-5.
11. Kurishima K, Satoh H, Ishikawa H, et al. Lung cancer patients with cardio- and cerebrovascular diseases. Oncol Rep 2001;8:1251-3.
12. Connolly CK, Crawford SM, Rider PL, et al. Carcinoma of the bronchus in the Yorkshire region of England 1976-1990: trends since 1984. Eur Respir J 1997;10:397-403.
13. Muers MF, Round CE. Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax 1993;48:339-43.
14. Radzikowska E, Roszkowski K, Glaz P. Lung cancer in patients under 50 years old. Lung Cancer 2001;33:203-11.
15. Deppermann KM. Influence of age and comorbidities on the chemotherapeutic management of lung cancer. Lung Cancer 2001;33(Suppl 1):S115-20.
16. British Thoracic Society. BTS guidelines on diagnostic flexible bronchoscopy. Thorax 2001;56(Suppl 1):i1-21.
17. Lechtzin N, Rubin HR, Jenckes M, et al. Predictors of pain control in patients undergoing flexible bronchoscopy. Am J Respir Crit Care Med 2000;162:440-5.
18. Knox AJ, Mascie-Taylor BH, Page RL. Fibreoptic bronchoscopy in the elderly: 4 years' experience. Br J Dis Chest 1988;82:290-3.
19. Macfarlane JT, Storr A, Wart MJ, et al. Safety, usefulness and acceptability of fibreoptic bronchoscopy in the elderly. Age Ageing 1981;10:127-31.
20. Hehn B, Haponik EF. Flexible bronchoscopy in the elderly. Clin Chest Med 2001;22:301-9, viii.
21. Peacock M, Johnson J, Blanton H. Complications of flexible bronchoscopy in patients with severe obstructive pulmonary disease. J Bronchol 1994;1:181-6.
22. Pue CA, Pacht ER. Complications of fiberoptic bronchoscopy at a university hospital. Chest 1995;107:430-2.
23. Dennie CJ, Matzinger FR, Marriner JR, et al. Transthoracic needle biopsy of the lung: results of early discharge in 506 outpatients. Radiology 2001;219:247-51.
24. Staroselsky AN, Schwarz Y, Man A, et al. Additional information from percutaneous cutting needle biopsy following fine-needle aspiration in the diagnosis of chest lesions. Chest 1998;113:1522-5.
25. Greif J, Staroselsky AN, Gernjac M, et al. Percutaneous core needle biopsy in the diagnosis of mediastinal tumors. Lung Cancer 1999;25:169-73.
26. Wiersema MJ, Vazquez-Sequeiros E, Wiersema LM. Evaluation of mediastinal lymphadenopathy with endoscopic US-guided fine-needle aspiration biopsy. Radiology 2001;219:252-7.
27. Brown TS, Kanthapillai P. Transthoracic needle biopsy for suspected thoracic malignancy in elderly patients using CT guidance. Clin Radiol 1998;53:116-9.
28. Hicks RJ, Kalff V, MacManus MP, et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001;42:1596-604.
29. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287-93.
30. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-61.
31. MacManus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001;92:886-95.
32. The Canadian Lung Oncology Group. Investigating extrathoracic metastatic disease in patients with apparently operable lung cancer. Ann Thorac Surg 2001;71:425-33; discussion 433-4.
33. British thoracic Society. Guidelines on the selection of patients with lung cancer for surgery. Thorax 2001;56:89-108.
34. de Perrot M, Licker M, Reymond MA, et al. Influence of age on operative mortality and long-term survival after lung resection for bronchogenic carcinoma. Eur Respir J 1999;14:419-22.
35. Pagni S, McKelvey A, Riordan C, et al. Pulmonary resection for malignancy in the elderly: is age still a risk factor? Eur J Cardiothorac Surg 1998;14:40-4; discussion 44-5.
36. Jazieh AR, Hussain M, Howington JA, et al. Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer. Ann Thorac Surg 2000;70:1168-71.
37. Riquet M, Medioni J, Manac'h D, et al. Non-small cell lung cancer: surgical trends as a function of age (in French). Rev Mal Respir 2001;18:173-84.
38. Filippetti M, Crucitti G, Andreetti C, et al. Experience of 10 years with the surgical treatment of lung cancer in elderly patients (in Italian). Chir Ital 2001;53:167-74.
39. Thomas P, Piraux M, Jacques LF, et al. Clinical patterns and trends of outcome of elderly patients with bronchogenic carcinoma. Eur J Cardiothorac Surg 1998;13:266-74.
40. Oliaro A, Leo F, Filosso PL, et al. Resection for bronchogenic carcinoma in the elderly. J Cardiovasc Surg (Torino) 1999;40:715-9.
41. Bouchardy C, Fioretta G, Perrot MD, et al. Determinant of long term survival after surgery for cancer of the lung: a population based study. Cancer 1999;86:2229-37.
42. Zhang D, Zhang R, Cheng G. The surgical treatment of lung cancer: a retrospective analysis of 2004 cases. Chin Med J (Engl) 1999;112:25-8.
43. Licker M, Spiliopoulos A, Frey JG, et al. Management and outcome of patients undergoing thoracic surgery in a regional chest medical centre. Eur J Anaesthesiol 2001;18:540-7.
44. Alexiou C, Beggs D, Rogers ML, et al. Pneumonectomy for non-small cell lung cancer: predictors of operative mortality and survival. Eur J Cardiothorac Surg 2001;20:476-80.
45. Bernard A, Deschamps C, Allen MS, et al. Pneumonectomy for malignant disease: factors affecting early morbidity and mortality. J Thorac Cardiovasc Surg 2001;121:1076-82.
46. Au J, el-Oakley R, Cameron EW. Pneumonectomy for bronchogenic carcinoma in the elderly. Eur J Cardiothorac Surg 1994;8:247-50.
47. Osaki T, Oyama T, Takenoyama M, et al. Results of surgical treatment for primary lung cancer; time trends of survival and clinicopathologic features (in Japanese). J Uoeh 2001;23:277-83.
48. UK Thoracic Surgical Register, 1994-96. Society of Cardiothoracic Surgeons of Great Britain and Ireland.
49. Roviaro G, Varoli F, Vergani C, et al. Techniques of pneumonectomy. Video-assisted thoracic surgery pneumonectomy. Chest Surg Clin N Am 1999;9:419-36, xi-xii.
50. Roviaro G, Varoli F, Nucca O, et al. Videothoracoscopic approach to primary mediastinal pathology. Chest 2000;117:1179-83.
51. Roviaro GC, Varoli F, Rebuffat C, et al. Videothoracoscopic operative staging for lung cancer. Int Surg 1996;81:252-4.
52. Jimenez MF. Prospective study on video-assisted thoracoscopic surgery in the resection of pulmonary nodules: 209 cases from the Spanish Video-Assisted Thoracic Surgery Study Group. Eur J Cardiothorac Surg 2001;19:562-5.
53. Lizza N, Eucher P, Haxhe JP, et al. Thoracoscopic resection of pulmonary nodules after computed tomographic-guided coil labeling. Ann Thorac Surg 2001;71:986-8.
54. Okumura T, Kondo H, Suzuki K, et al. Fluoroscopy-assisted thoracoscopic surgery after computed tomography-guided bronchoscopic barium marking. Ann Thorac Surg 2001;71:439-42.
55. Solaini L, Prusciano F, Bagioni P, et al. Video-assisted thoracic surgery major pulmonary resections. Present experience. Eur J Cardiothorac Surg 2001;20:437-42.
56. Shiraishi T, Yoshinaga Y, Yoneda S, et al. Clinical evaluation of VATS lobectomy for lung cancer (in Japanese). Kyobu Geka 2000;53:4-7.
57. McKenna RJ Jr, Wolf RK, Brenner M, et al. Is lobectomy by video-assisted thoracic surgery an adequate cancer operation? Ann Thorac Surg 1998;66:1903-8.
58. Roviaro G, Varoli F, Vergani, et al. Video-assisted thoracoscopic surgery (VATS) major pulmonary resections: the Italian experience. Semin Thorac Cardiovasc Surg 1998;10:313-20.
59. Ohbuchi T, Morikawa T, Takeuchi E, et al. Lobectomy: video-assisted thoracic surgery versus posterolateral thoracotomy. Jpn J Thorac Cardiovasc Surg 1998;46:519-22.
60. Sugiura H, Morikawa T, Kaji M, et al. Long-term benefits for the quality of life after video-assisted thoracoscopic lobectomy in patients with lung cancer. Surg Laparosc Endosc Percutan Tech 1999;9:403-8.
61. Nagahiro I, Andou A, Aoe M, et al. Pulmonary function, postoperative pain, and serum cytokine level after lobectomy: a comparison of VATS and conventional procedure. Ann Thorac Surg 2001;72:362-5.
62. Mikami I, Koizumi K, Tanaka S. Changes in right ventricular performance in elderly patients who underwent lobectomy using video-assisted thoracic surgery for primary lung cancer. Jpn J Thorac Cardiovasc Surg 2001;49:153-9.
63. Takahashi N, Tsunematsu K, Sugawara H, et al. Limited thoracotomy as surgical therapy for lung cancer: lobectomy and lymph node dissection by means of 12 cm skin incision (in Japanese). Kyobu Geka 2001;54:197-202.
64. Inaoka M, Obama T, Kawaharada N. Video-assisted minithoracotomy versus conventional posterolateral thoracotomy for performing lobectomy of lung carcinomas (in Japanese). Kyobu Geka 2000;53:18-21.
65. Yoshimura M, Tsubota N. Wedge resection for lung cancer (in Japanese). Nippon Geka Gakkai Zasshi 200;102:521-4.
66. Sagawa M, Koike T, Sato M, et al. Segmentectomy for roentgenographically occult bronchogenic squamous cell carcinoma. Ann Thorac Surg 2001;71:1100-4.
67. Yamato Y, Tsuchida M, Watanabe T, et al. Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung. Ann Thorac Surg 2001;71:971-4.
68. Korst RJ, Ginsberg RJ. Appropriate surgical treatment of resectable non-small-cell lung cancer. World J Surg 2001;25:184-8.
69. Santambrogio L, Nosotti M, Baisi A, et al. Pulmonary lobectomy for lung cancer: a prospective study to compare patients with forced expiratory volume in 1 s more or less than 80% of predicted. Eur J Cardiothorac Surg 2001;20:684-7.
70. Hayashi K, Fukushima K, Sagara Y, et al. Surgical treatment for patients with lung cancer complicated by severe pulmonary emphysema. Jpn J Thorac Cardiovasc Surg 1999;47:583-7.
71. Edwards JG, Duthie DJ, Waller DA. Lobar volume reduction surgery: a method of increasing the lung cancer resection rate in patients with emphysema. Thorax 2001;56:791-5.
72. Korst RJ, Ginsberg RJ, Ailawadi M, et al. Lobectomy improves ventilatory function in selected patients with severe COPD. Ann Thorac Surg 1998;66:898-902.
73. Pagni S, Federico JA, Ponn RB. Pulmonary resection for lung cancer in octogenarians. Ann Thorac Surg 1997;63:785-9.
74. Hanagiri T, Muranaka H, Hashimoto M, et al. Results of surgical treatment of lung cancer in octogenarians. Lung Cancer 1999;23:129-33.
75. Kobayashi S, Okada S, Hasumi T, et al. Long-term survival of a poor-risk octogenarian following wedge resection under VATS for small-cell lung cancer: report of a case. Surg Today 2000;30:286-90.
76. Inoue N, Kosino T, Abe T. A case treated with thoracoscopic wedge resection for cT1N0M0 lung cancer complicated with both chronic obstructive pulmonary disease (COPD) and hypofunction of left ventricle in a octogenarian. Kyobu Geka 2001;54:164-7.
77. British Thoracic Society/Society of Cardiothoracic Surgeons of Great Britain and Ireland. The critical under provision of thoracic surgery in the UK. Report of a Joint Working Group of the British Thoracic Society and the Society of Cardiothoracic Surgeons of Great Britain and Ireland, 2001.
78. Partridge M. Thoracic surgery in crisis. BMJ 2002;324:376-7.
79. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax 2001;56:628-38.
80. Hayakawa K, Mitsuhashi N, Katano S, et al. High-dose radiation therapy for elderly patients with inoperable or unresectable non-small cell lung cancer. Lung Cancer 2001;32:81-8.
81. Langendijk JA, Aaronson NK, de Jong JM, et al. Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J Clin Oncol 2001;19:2123-33.
82. Gauden SJ, Tripcony L. The curative treatment by radiation therapy alone of stage I non-small cell lung cancer in a geriatric population. Lung Cancer 2001;32:71-9.
83. Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst 1994;86:1766-70.
84. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998;317:771-5.
85. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995;76:593-601.
86. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
87. Sim S, Rosenzweig KE, Schindelheim R, et al. Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001;51:660-5.
88. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9.
89. Movsas B, Scott C, Curran W, et al. A quality adjusted time without symptoms of toxicity analysis of radiation therapy oncology group 94-10 (abstract 1247). Proc Am Soc Clin Oncol 2001;20:313a.
90. Curran W, Scott C, Langer C, et al. Phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (abstract 1891). Proc Am Soc Clin Oncol 2000;19:484a.
91. Gaspar LE. Optimizing chemoradiation therapy approaches to unresectable stage III non-small cell lung cancer. Curr Opin Oncol 2001;13:110-5.
92. Jeremic B, Shibamoto Y. Pre-treatment prognostic factors in patients with stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy. Lung Cancer 1995;13:21-30.
93. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-94.
94. Earle CC, Tsoi JS, Gelber RD, et al. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 2001;19:1064-70.
95. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27:145-57.
96. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
97. Yokoyama A, Furuse K, Kurita Y, et al. Gemcitabine as a single agent in the treatment of elderly (>70 years) patients with stage III-IV NSCLC as compared to those <70 yearsold (abstract 2056). Proc Am Soc Clin Oncol 2000;19:523a.
98. Martoni A, Fabio FD, Guaraldi M, et al. Gemcitabine as single agent in the treatment of elderly patients with stage IIIb-IV NSCLC: preliminary results of an Italian multicentre study (abstract 1991). Proc Am Soc Clin Oncol 1999;18:517a.
99. Ricci S, Antouzzo A, Galli L, et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer. A multicentre phase II study. Lung Cancer 2000;27:75-80.
100. Shepherd F, Abratt R, Anderson H. Gemcitabine in the treatment of elderly patients with advanced NSCLC. Semin Oncol 1997;24(Suppl 7):50-5.
101. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000;18:2529-36.
102. Gridelli C, Cigolari S, Bilancia D. Phase II study of gemcitabine and gemcitabine plus vinorelbine in advanced NSCLC elderly patients within the phase III MILES randomised trial (abstract 2092). Proc Am Soc Clin Oncol 2000;19:532a.
103. Gridelli C, Perrone P, Cigolari S, et al. The MILES phase III trial: Gemcitabine plus vinorelbine versus vinorelbine and versus gemcitabine in elderly advanced NSCLC (abstract 1230). Proc Am Soc Clin Oncol 2001;20:308a.
104. Nguyen B, Sandler A, Denham C. The safety and efficacy of gemcitabine plus cisplatin in the elderly chemonaive NSCLC patients (age >70 years) as compared to those with age <70 years. Proc Am Soc Clin Oncol 1999;18:471a.
105. Lippe P, Silva R, Monterubbianesi M, et al. Advanced NSCLC in the elderly: Symptoms relief after weekly gemcitabine and cisplatin (abstract 1984). Proc Am Soc Clin Oncol 1999;18:514a.
106. Feliu J, Martin G, Rodriguez-Jaraiz M, et al. Phase II trial of low dose cisplatin plus gemcitabine in elderly patients with advanced NSCLC. Preliminary results (abstract 2763). Proc Am Soc Clin Oncol 2001;20:253b.
107. Maestu I, Torregrossa D, Llorca C, et al. Efficacy of carboplatin and gemcitabine in the treatment of elderly patients with advanced NSCLC (abstract 1599). Proc Am Soc Clin Oncol 2001;20:401a.
108. Martins S, Pereira J, Ikari F, et al. Chemotherapy with cisplatin and vinorelbine for elderly NSCLC patients (abstract 1804). Proc Am Soc Clin Oncol 1999;18:468a.
109. Hainsworth JD, Burris HA 3rd, Greco FA. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer. Semin Oncol 2001;28(3 Suppl 9):21-5.
110. Fidias P, Supko J, Martins R, et al. A Phase II study of weekly poclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001;7:3942-9.
111. Connolly CK, Jones WG, Thorogood J, et al. Investigation, treatment and prognosis of bronchial carcinoma in the Yorkshire Region of England 1976-1983. Br J Cancer 1990;61:579-83.
112. Janne P, Friedlin B, Soxman S, et al. The survival of patients treated for limited stage small-cell lung cancer in North America has increased during the past 20 years (abstract 1264). Proc Am Soc Clin Oncol 2001;20:317a.
113. Lebitasy MP, Hedelin G, Purohit A, et al. Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994. Br J Cancer 2001;85:808-15.
114. Camps C, Artal A, Gomez-Codina J, et al. Age as a prognostic factor in Small-cell lung cancer: randomised trial of high-dose epirubicin-cisplatin versus cisplatin-etoposide in SCLC. A retrospective analysis (abstract 2871). Proc Am Soc Clin Oncol 2001;20:280b.
115. Albain KS, Crowley JJ, LeBlanc M, et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:1563-74.
116. Remiszewski P, Slodkowska J, Wiatr E, et al. Fatal infection in patients treated for small cell lung cancer in the Institute of Tuberculosis and Chest Diseases in the years 1980-1994. Lung Cancer 2001;31:101-10.
117. Oshita F, Yamada K, Nomura I, et al. Randomized study of dose or schedule modification of granulocyte colony-stimulating factor in platinum-based chemotherapy for elderly patients with lung cancer. Oncol Rep 2001;8:861-6.
118. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 2001;12:1359-68.
119. Jeremic B, Shibamoto Y, Acimovic L, et al. Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma: a phase II study. Cancer 1998;B2:836-41.
120. Westeel V, Murray N, Gelmon K, et al. New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen. J Clin Oncol 1998;16:1940-7.
121. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71.
122. Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 2000;89:1953-60.
123. Pujol JL, Daures JP, Riviere A, et al. Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001;93:300-8.
124. Matsui K, Masuda N, Fukuoka M, et al. Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. Br J Cancer 1998;77:1961-5.
125. Grunberg SM, Crowley J, Hande KR, et al. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide: a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemother Pharmacol 1999;44:461-8.
126. White SC, Lorigan P, Middleton MR, et al. Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. Cancer 2001;92:601-8.
127. Hickish TF, Smith IE, Nicolson MC, et al. A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer. Br J Cancer 1998;77:1966-70.
128. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
129. Steele JP. Gemcitabine/carboplatin versus cisplatin/etoposide for patients with poor-prognosis small cell lung cancer: a phase III randomized trial with quality-of-life evaluation. Semin Oncol 2001;28 (3 Suppl 10):15-8.
130. Marinis FD, Cortesi E, Pauluzzi L, et al. Cisplatin, etoposide and gemcitabine in untreated patients with small-cell lung cancer: preliminary results of a multi-institutional phase II trial (abstract 2062). Proc Am Soc Clin Oncol 2000;19:525a.
131. Dunlop D, Connery L, O'Brien M, et al. Phase II study of carboplatin (AUC5) and vinorelbine in small cell lung cancer (abstract 2033). Proc Am Soc Clin Oncol 2000;19:519a.
132. Mok T, Chan A, Leung T, et al. Sequential administration of topotecan and oral etoposide in the treatment of small cell lung cancer (abstract 2018). Proc Am Soc Clin Oncol 2000;19:515a.
133. Cerny T, Blair V, Anderson H, et al. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987;39:146-9.
134. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1997;33:1752-8.
135. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476-84.
136. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-24.
137. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited stage small cell lung cancer? A meta-analysis. J Clin Oncol 1992;10:890-5.
138. Quon H, Shepherd FA, Payne DG, et al. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 1999;43:39-45.
139. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993;11:336-44.
140. Jeremic B, Shibamoto Y, Acimovic L, et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997;15:893-900.
141. Tsukada H, Yokoyama A, Goto K, et al. Concurrent versus sequential radiotherapy for small cell lung cancer. Semin Oncol 2001;28(2 Suppl 4):23-6.
142. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987;316:912-8.
143. Perry MC, Herndon 3rd JE, Eaton WL, et al. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. J Clin Oncol 1998;16:2466-7.
144. Work E, Nielsen OS, Bentzen SM, et al. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. J Clin Oncol 1997;15:3030-7.
145. Murray N, Grafton C, Shah A, et al. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol 1998;16:3323-8.
146. Rea F, Callegaro D, Favaretto A, et al. Long term results of surgery and chemotherapy in small cell lung cancer. Eur J Cardiotharac Surg 1998;14:398-402.
147. Turrisi AT, Sherman CA. The treatment of limited small cell lung cancer. a report of the progress made and future prospects. Eur J Cancer 2002;38:279-91.
148. Massard G, Moog R, Wihlm JM, et al. Bronchogenic cancer in the elderly: operative risk and long-term prognosis. Thorac Cardiovasc Surg 1996;44:40-5.
149. Giorgio A, Arnone D, Casali G, et al. Surgical excisions of lung neoplasms in the elderly. Minerva Chir 1994;49:917-27.
150. Roxburgh JC, Thompson J, Goldstraw P. Hospital mortality and long-term survival after pulmonary resection in the elderly. Ann Thorac Surg 1991;51:800-3.
151. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633-41.
152. Ganz PA, Figlin RA, Haskell CM, et al. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer 1989;63:1271-8.
153. Helsing M, Bergman B, Thaning L, et al. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 1998;34:1036-44.
154. Thongprasert S, Sanguanmitra P, Juthapan W, et al. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999;24:17-24.
155. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1074-80.
156. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
157. Anderson H, Hopwood R, Stephens J, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000;83:447-53.
158. Bianco V, Di Girolamo B, Pignatelli E, et al. Gemcitabine as single agent therapy in advanced non small cell lung cancer and quality of life in the elderly. Panminerva Med 2001;43:15-9.
159. Manegold C. Treatment of elderly patients with non-small-cell lung cancer. Oncology 2001;15(3 Suppl 6):46-51.